, WHO. WHO j Data and statistics. Geneva: WHO, 2013.
, Geneva: World Health Organization, WHO. WHO j Consolidated ARV guidelines 2013, 2013.
HIV treatment and care in resource-constrained environments: challenges for the next decade, J Int AIDS Soc, vol.15, issue.2, p.17334, 2012. ,
UNAIDS study finds no real change in donor funding for HIV, 2013. ,
Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries, Curr Opin HIV AIDS, vol.5, pp.237-278, 2010. ,
, Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organization, 2009.
, Generic Med, vol.7, pp.159-75, 2010.
Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases, Bull World Health Organ, vol.87, pp.520-528, 2009. ,
HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare? PLoS One, vol.2, p.278, 2007. ,
Decrease in prices of antiretroviral drugs for developing countries: from political ''philanthropy'' to regulated markets, Issues and challenges. France: ANRS, pp.169-211, 2003. ,
Factors influencing global antiretroviral procurement prices, BMC Public Health, 2009. ,
,
Modeling HIV/AIDS medicine price determinants in Brazil: is generic competition a myth?, PLoS One, vol.6, p.23478, 2011. ,
Global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets, Global Health, vol.6, p.9, 2010. ,
Guide d. analyse e ´conomique du circuit du médicament' Genè ve: Organisation mondiale de la Santé, 2001. ,
URL : https://hal.archives-ouvertes.fr/hal-00851040
The world medicines situation 2011. Geneva: World Health Organization, 2011. ,
UNAIDS. Doha'10 trips flexibilities and access to antiretroviral therapy: lessons from the past, opportunities for the future. Geneva: UNAIDS; 2011. 18. UNAIDS. Implementation of TRIPS and access to medicines for HIV after, strategies and options for least developed countries, vol.17, 2011. ,
, Health Policy Project, 2011.
Good practice guide: improving access to treatment by utilizing public health flexibilities in the WTO TRIPS agreement, Health Policy Plan, vol.22, pp.63-72, 2007. ,
Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements, Cad Saude Publica, vol.23, 2007. ,
The relation of price of antiretroviral medicines and foreign assistance with coverage of HIV treatment in Africa: retrospective study, J Econ Perspect, vol.341, pp.45-66, 2002. ,
Generic entry, price competition, and market segmentation in the prescription medicine market, Int J Ind Organ, vol.26, pp.930-978, 2008. ,
Generic medicine industry dynamics, Rev Econ Stat, vol.87, issue.1, pp.37-49, 2005. ,
Investments in pharmaceuticals before and after TRIPS, Rev Econ Stat, vol.94, issue.4, pp.1157-72, 2012. ,
, Journal of the International AIDS Society, vol.19, 2016.
,
, Gross National Income per capita) 0.1649*** (0.1399, 0.1900) 0.0698*** (0.0616, 0.0781) log(Quantity purchased per transaction, Sub-Saharan Africa log
, Journal of the International AIDS Society, vol.19, 2016.
3396) Ref: B5 years Number of observed suppliers (0.0266*** ,
, World Bank classification of developing regions; b given that the dataset used in the study comprises transactions from 2003 to 2nd quarter 2015, the therapeutic class accounts for the changes in WHO guidelines (time-varying variable); c as suggested by the polynomial regression technique, exponents were introduced until the estimated coefficients are not significant
, Journal of the International AIDS Society, vol.19, 2016.